TY - JOUR
T1 - Tuberculosis drug resistance
T2 - A global threat
AU - Nachega, Jean B.
AU - Chaisson, Richard E.
N1 - Funding Information:
Grant support: NIH AI01637 and AI45432 (R.E.C.) and the US Agency for International Development.
PY - 2003/1/15
Y1 - 2003/1/15
N2 - Resistance to antituberculosis drugs has been a problem since the era of chemotherapy began. After dramatic outbreaks of multidrug-resistant tuberculosis (MDR-TB) in the early 1990s, resistance became recognized as a global problem. MDR-TB now threatens the inhabitants of countries in Europe, Asia, Africa, and the Americas. An understanding of the molecular basis of drug resistance may contribute to the development of new drugs. Management of MDR-TB relies on prompt recognition and treatment with at least 3 drugs to which an isolate is susceptible.
AB - Resistance to antituberculosis drugs has been a problem since the era of chemotherapy began. After dramatic outbreaks of multidrug-resistant tuberculosis (MDR-TB) in the early 1990s, resistance became recognized as a global problem. MDR-TB now threatens the inhabitants of countries in Europe, Asia, Africa, and the Americas. An understanding of the molecular basis of drug resistance may contribute to the development of new drugs. Management of MDR-TB relies on prompt recognition and treatment with at least 3 drugs to which an isolate is susceptible.
UR - http://www.scopus.com/inward/record.url?scp=0037439496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037439496&partnerID=8YFLogxK
U2 - 10.1086/344657
DO - 10.1086/344657
M3 - Article
C2 - 12516027
AN - SCOPUS:0037439496
SN - 1058-4838
VL - 36
SP - S24-S30
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 1
ER -